透景生命收盘下跌4.15%，滚动市盈率71.33倍，总市值28.17亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, TuoJing Life, within the medical device industry, indicating a significant drop in revenue despite an increase in net profit [1][2] - As of August 5, TuoJing Life's stock closed at 17.33 yuan, down 4.15%, with a rolling PE ratio of 71.33 times, and a total market capitalization of 2.817 billion yuan [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing TuoJing Life at the 94th position in the industry ranking [1][2] Group 2 - In terms of capital flow, TuoJing Life experienced a net outflow of 28.6258 million yuan on August 5, with a total outflow of 19.8639 million yuan over the past five days [1] - The company's main business involves the research, production, and sales of in vitro diagnostic products, including diagnostic reagents and instruments [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, while net profit was 471,700 yuan, reflecting a year-on-year increase of 110.51%, with a gross profit margin of 63.66% [1]